|Bid||4.6400 x 2200|
|Ask||4.6500 x 800|
|Day's Range||4.5900 - 4.7600|
|52 Week Range||3.9500 - 19.9400|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.67|
CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 633,631 shares of XON on 05/21/2019 at an average price of $4.65 a share.
Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * Bearish sentiment is moderate and declining Bearish sentimentShort interest | NeutralShort interest is moderately high for XON with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on April 25. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold XON had net inflows of $918 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.Intrexon XON : "This is a loser and I don't want to hear about it.
Intrexon Corp. (NASDAQ: XON) Chairman and CEO Randal Kirk has snapped up a bigger share of his public bioengineering company. Kirk controls Radford, Virginia-based venture capital firm Third Security LLC, which manages Third Security Capital Partners, Kapital Joe and NRM VI Holdings — all of which own Intrexon stock. In all, Kirk and his affiliates spent more than $9.2 million on the shares in mid-May, public filings show.
CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 1,257,727 shares of XON on 05/15/2019 at an average price of $4.4 a share.
GERMANTOWN, Md., May 13, 2019 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Randal J. Kirk, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas on Wednesday, May 15th, at 3:40 p.m. Pacific Time. Mr. Kirk will focus on Intrexon Health's development of targeted, controllable, multigenic therapeutics for the treatment of complex diseases and unmet medical needs, highlighting the therapeutic candidates currently in clinical development. A live webcast of the presentation will be available on the Investors section of Intrexon's website at https://investors.dna.com/events, and a replay of the webcast will be available for 30 days following the event.
GERMANTOWN, Md., May 9, 2019 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results for 2019. Intrexon announced alignment of its operations into two units, Intrexon Health and Intrexon Bioengineering, to better deploy resources, realize inherent synergies and position the company for growth with a core focus on healthcare.
MAYNARD, Mass., May 02, 2019 -- AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.
GERMANTOWN, Md. , May 2, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GERMANTOWN, Md. , April 29, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
-Nearly 5,000 square foot facility will manufacture early stage clinical trial material for gene therapy trials GERMANTOWN, Md. , April 25, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary ...
MAYNARD, Mass., April 17, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries OXFORD, England , April 16, 2019 /PRNewswire/ -- Oxitec ...
Fibrocell Science, Inc. (FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagnosed at infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA). “We are proud to partner with Castle Creek Pharmaceuticals, a company recognized for its innovation in drug development for rare skin diseases and its commitment to the epidermolysis bullosa community.
GERMANTOWN, Md. , April 10, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
MAYNARD, Mass., April 09, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.
OXFORD, England, April 9, 2019 /PRNewswire/ -- Oxitec Ltd., a wholly-owned subsidiary of Intrexon (XON), today announced it has entered into a second agreement with a collaborator to advance the next phase of development of its self-limiting fall armyworm control solution. This announcement comes after the successful conclusion of an initial three-year research and development collaboration that funded the early development of the self-limiting fall armyworm strain.